2-Year OS Improves Over 20 Years in Relapsed Ph+ ALL Post Allogeneic Transplant
OncLive,
The 2-year overall survival rate almost doubled between 2000 and 2004 and 2015 and 2019 in patients with Philadelphia chromosome…
The 2-year overall survival rate almost doubled between 2000 and 2004 and 2015 and 2019 in patients with Philadelphia chromosome…
(HealthDay News) — Real-world data show steady improvement in overall survival (OS) for patients with Philadelphia-positive (Ph+…
Real-world data show steady improvement in overall survival (OS) for patients with Philadelphia-positive (Ph+) acute…
TUESDAY, Jan. 18, 2022 (HealthDay News) — Real-world data show steady improvement in overall survival (OS) for patients with…